|
HY-15583-10mg
|
MedChemexpress LLC
|
Auristatin F [CAS 163768-50-1]
|
|
Cancer-programmed cell death
|
|
|
HY-15583-100mg
|
MedChemexpress LLC
|
Auristatin F [CAS 163768-50-1]
|
|
Cancer-programmed cell death
|
|
|
HY-15583-5mg
|
MedChemexpress LLC
|
Auristatin F [CAS 163768-50-1]
|
|
Cancer-programmed cell death
|
|
|
HY-15583-50mg
|
MedChemexpress LLC
|
Auristatin F [CAS 163768-50-1]
|
|
Cancer-programmed cell death
|
|
|
HY-19318-1g
|
MedChemexpress LLC
|
Fmoc-Val-Cit-PAB [CAS 159858-22-7]
|
|
Cancer-programmed cell death
|
|
|
HY-19318-250mg
|
MedChemexpress LLC
|
Fmoc-Val-Cit-PAB [CAS 159858-22-7]
|
|
Cancer-programmed cell death
|
|
|
HY-19318-500mg
|
MedChemexpress LLC
|
Fmoc-Val-Cit-PAB [CAS 159858-22-7]
|
|
Cancer-programmed cell death
|
|
|
HY-P990027-1mg
|
MedChemexpress LLC
|
Izeltabart [CAS 2642078-60-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P990027-10mg
|
MedChemexpress LLC
|
Izeltabart [CAS 2642078-60-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P990027-5mg
|
MedChemexpress LLC
|
Izeltabart [CAS 2642078-60-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P99101-1mg
|
MedChemexpress LLC
|
Vobramitamab [CAS 2490556-50-6]
|
|
|
|
|
HY-P99101-10mg
|
MedChemexpress LLC
|
Vobramitamab [CAS 2490556-50-6]
|
|
|
|
|
HY-P99101-5mg
|
MedChemexpress LLC
|
Vobramitamab [CAS 2490556-50-6]
|
|
|
|
|
HY-P99612-1mg
|
MedChemexpress LLC
|
Farletuzumab ecteribulin [CAS 2407465-18-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99612-10mg
|
MedChemexpress LLC
|
Farletuzumab ecteribulin [CAS 2407465-18-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99612-5mg
|
MedChemexpress LLC
|
Farletuzumab ecteribulin [CAS 2407465-18-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99682-1mg
|
MedChemexpress LLC
|
Ladiratuzumab [CAS 1629760-28-6]
|
|
Cancer-programmed cell death
|
|
|
HY-P99682-10mg
|
MedChemexpress LLC
|
Ladiratuzumab [CAS 1629760-28-6]
|
|
Cancer-programmed cell death
|
|
|
HY-P99682-5mg
|
MedChemexpress LLC
|
Ladiratuzumab [CAS 1629760-28-6]
|
|
Cancer-programmed cell death
|
|
|
HY-P9985-1mg
|
MedChemexpress LLC
|
Disitamab vedotin [CAS 2136633-23-1]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9985-10mg
|
MedChemexpress LLC
|
Disitamab vedotin [CAS 2136633-23-1]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9985-5mg
|
MedChemexpress LLC
|
Disitamab vedotin [CAS 2136633-23-1]
|
|
Cancer-Kinase/protease
|
|
|
HY-W019939-100mg
|
MedChemexpress LLC
|
Hydroxy-PEG10-Boc [CAS 778596-26-2]
|
|
Cancer-programmed cell death
|
|
|
HY-W019939-250mg
|
MedChemexpress LLC
|
Hydroxy-PEG10-Boc [CAS 778596-26-2]
|
|
Cancer-programmed cell death
|
|
|
HY-W731085-10mg
|
MedChemexpress LLC
|
MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH [CAS 2626930-84-3]
|
|
|
|
